Investigating Variations in Medicine Approvals for Attention-Deficit/Hyperactivity Disorder: A Cross-Country Document Analysis Comparing Drug Labeling.

Autor:	Tanana L; School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia., Latif A; University of Nottingham, Nottingham, UK., Nishtala PS; Department of Life Sciences, University of Bath, Bath, UK., Chen TF; School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Jazyk:	angličtina
Zdroj:	Journal of attention disorders [J Atten Disord] 2024 Sep; Vol. 28 (11), pp. 1437-1453. Date of Electronic Publication: 2024 Feb 07.
DOI:	10.1177/10870547231224088
Abstrakt:	Objective: This study aimed to compare the approval of medicines for attention deficit/hyperactivity disorder (ADHD) for pediatric patients across five countries. Method: A document analysis was completed, using the drug labeling for ADHD medicines from five countries; United Kingdom, Australia, New Zealand, Canada and United States (US). Comparisons of available formulations and approval information for ADHD medicine use in pediatric patients were made. Results: The US had the highest number of approved medicines and medicine forms across the studied countries (29 medicine forms for 10 approved medicines). Approved age and dosage variations across countries and missing dosage information were identified in several drug labeling. Conclusions: The discrepancies in approval information in ADHD medicine drug labeling and differing availability of medicine formulations across countries suggest variations in the management of ADHD across countries. The update of drug labeling and further research into reasons for variability and impact on practice are needed. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu